U.S., Feb. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07417813) titled 'A Multicenter Observational Study of Lemborexant on Insomnia Patients With Psychiatric Disorders' on Jan. 29.
Brief Summary: This study aims to evaluate the effectiveness and safety of lemborexant (a new dual orexin receptor antagonist) in the treatment of patients with mental disorders complicated with insomnia. The subjects are patients aged 18 years and above, who meet the DSM-5 diagnostic criteria for mental disorders and have an Insomnia Severity Index (ISI) score >=11. They will receive lemborexant treatment for 8 weeks, with follow-up to observe the improvement of insomnia symptoms and adverse events, so as to provide real-wo...